Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

LRRK2 activation in idiopathic Parkinson's disease.

Di Maio R, Hoffman EK, Rocha EM, Keeney MT, Sanders LH, De Miranda BR, Zharikov A, Van Laar A, Stepan AF, Lanz TA, Kofler JK, Burton EA, Alessi DR, Hastings TG, Greenamyre JT.

Sci Transl Med. 2018 Jul 25;10(451). pii: eaar5429. doi: 10.1126/scitranslmed.aar5429.

PMID:
30045977
2.

Inhibition of 2-AG hydrolysis differentially regulates blood brain barrier permeability after injury.

Piro JR, Suidan GL, Quan J, Pi Y, O'Neill SM, Ilardi M, Pozdnyakov N, Lanz TA, Xi H, Bell RD, Samad TA.

J Neuroinflammation. 2018 May 14;15(1):142. doi: 10.1186/s12974-018-1166-9.

3.

Interactome analysis reveals ZNF804A, a schizophrenia risk gene, as a novel component of protein translational machinery critical for embryonic neurodevelopment.

Zhou Y, Dong F, Lanz TA, Reinhart V, Li M, Liu L, Zou J, Xi HS, Mao Y.

Mol Psychiatry. 2018 Apr;23(4):952-962. doi: 10.1038/mp.2017.166. Epub 2017 Sep 19.

4.

Transcriptional Profiling of a Selective CREB Binding Protein Bromodomain Inhibitor Highlights Therapeutic Opportunities.

Chekler EL, Pellegrino JA, Lanz TA, Denny RA, Flick AC, Coe J, Langille J, Basak A, Liu S, Stock IA, Sahasrabudhe P, Bonin PD, Lee K, Pletcher MT, Jones LH.

Chem Biol. 2015 Dec 17;22(12):1588-96. doi: 10.1016/j.chembiol.2015.10.013. Epub 2015 Dec 3.

5.

Evaluation of TrkB and BDNF transcripts in prefrontal cortex, hippocampus, and striatum from subjects with schizophrenia, bipolar disorder, and major depressive disorder.

Reinhart V, Bove SE, Volfson D, Lewis DA, Kleiman RJ, Lanz TA.

Neurobiol Dis. 2015 May;77:220-7. doi: 10.1016/j.nbd.2015.03.011. Epub 2015 Mar 18.

PMID:
25796564
6.

STEP levels are unchanged in pre-frontal cortex and associative striatum in post-mortem human brain samples from subjects with schizophrenia, bipolar disorder and major depressive disorder.

Lanz TA, Joshi JJ, Reinhart V, Johnson K, Grantham LE 2nd, Volfson D.

PLoS One. 2015 Mar 18;10(3):e0121744. doi: 10.1371/journal.pone.0121744. eCollection 2015.

7.

Downstream effects of striatal-enriched protein tyrosine phosphatase reduction on RNA expression in vivo and in vitro.

Reinhart VL, Nguyen T, Gerwien R Jr, Kuhn M, Yates PD, Lanz TA.

Neuroscience. 2014 Oct 10;278:62-9. doi: 10.1016/j.neuroscience.2014.08.002. Epub 2014 Aug 15.

PMID:
25130559
8.

Behavioral characterization of striatal-enriched protein tyrosine phosphatase (STEP) knockout mice.

Sukoff Rizzo SJ, Lotarski SM, Stolyar P, McNally T, Arturi C, Roos M, Finley JE, Reinhart V, Lanz TA.

Genes Brain Behav. 2014 Sep;13(7):643-52. doi: 10.1111/gbb.12169. Epub 2014 Aug 28.

9.

Transcriptomic analysis of genetically defined autism candidate genes reveals common mechanisms of action.

Lanz TA, Guilmette E, Gosink MM, Fischer JE, Fitzgerald LW, Stephenson DT, Pletcher MT.

Mol Autism. 2013 Nov 15;4(1):45. doi: 10.1186/2040-2392-4-45.

10.

A survey of rare coding variants in candidate genes in schizophrenia by deep sequencing.

Hu X, Zhang B, Liu W, Paciga S, He W, Lanz TA, Kleiman R, Dougherty B, Hall SK, McIntosh AM, Lawrie SM, Power A, John SL, Blackwood D, St Clair D, Brandon NJ.

Mol Psychiatry. 2014 Aug;19(8):857-8. doi: 10.1038/mp.2013.131. Epub 2013 Oct 15. No abstract available.

11.

Robust changes in expression of brain-derived neurotrophic factor (BDNF) mRNA and protein across the brain do not translate to detectable changes in BDNF levels in CSF or plasma.

Lanz TA, Bove SE, Pilsmaker CD, Mariga A, Drummond EM, Cadelina GW, Adamowicz WO, Swetter BJ, Carmel S, Dumin JA, Kleiman RJ.

Biomarkers. 2012 Sep;17(6):524-31. doi: 10.3109/1354750X.2012.694476. Epub 2012 Jun 7.

PMID:
22672085
12.

MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function.

Miller BH, Zeier Z, Xi L, Lanz TA, Deng S, Strathmann J, Willoughby D, Kenny PJ, Elsworth JD, Lawrence MS, Roth RH, Edbauer D, Kleiman RJ, Wahlestedt C.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3125-30. doi: 10.1073/pnas.1113793109. Epub 2012 Feb 6.

13.

Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease.

La Porte SL, Bollini SS, Lanz TA, Abdiche YN, Rusnak AS, Ho WH, Kobayashi D, Harrabi O, Pappas D, Mina EW, Milici AJ, Kawabe TT, Bales K, Lin JC, Pons J.

J Mol Biol. 2012 Aug 24;421(4-5):525-36. doi: 10.1016/j.jmb.2011.11.047. Epub 2011 Dec 13.

PMID:
22197375
14.

Design, synthesis, and in vivo characterization of a novel series of tetralin amino imidazoles as γ-secretase inhibitors: discovery of PF-3084014.

Brodney MA, Auperin DD, Becker SL, Bronk BS, Brown TM, Coffman KJ, Finley JE, Hicks CD, Karmilowicz MJ, Lanz TA, Liston D, Liu X, Martin BA, Nelson RB, Nolan CE, Oborski CE, Parker CP, Richter KE, Pozdnyakov N, Sahagan BG, Schachter JB, Sokolowski SA, Tate B, Wood DE, Wood KM, Van Deusen JW, Zhang L.

Bioorg Med Chem Lett. 2011 May 1;21(9):2637-40. doi: 10.1016/j.bmcl.2010.12.118. Epub 2010 Dec 30.

PMID:
21269827
15.

Diamide amino-imidazoles: a novel series of γ-secretase inhibitors for the treatment of Alzheimer's disease.

Brodney MA, Auperin DD, Becker SL, Bronk BS, Brown TM, Coffman KJ, Finley JE, Hicks CD, Karmilowicz MJ, Lanz TA, Liston D, Liu X, Martin BA, Nelson RB, Nolan CE, Oborski CE, Parker CP, Richter KE, Pozdnyakov N, Sahagan BG, Schachter JB, Sokolowski SA, Tate B, Van Deusen JW, Wood DE, Wood KM.

Bioorg Med Chem Lett. 2011 May 1;21(9):2631-6. doi: 10.1016/j.bmcl.2010.12.117. Epub 2010 Dec 30.

PMID:
21269825
16.

Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease.

Kleiman RJ, Kimmel LH, Bove SE, Lanz TA, Harms JF, Romegialli A, Miller KS, Willis A, des Etages S, Kuhn M, Schmidt CJ.

J Pharmacol Exp Ther. 2011 Jan;336(1):64-76. doi: 10.1124/jpet.110.173294. Epub 2010 Oct 5.

17.

Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.

Lanz TA, Wood KM, Richter KE, Nolan CE, Becker SL, Pozdnyakov N, Martin BA, Du P, Oborski CE, Wood DE, Brown TM, Finley JE, Sokolowski SA, Hicks CD, Coffman KJ, Geoghegan KF, Brodney MA, Liston D, Tate B.

J Pharmacol Exp Ther. 2010 Jul;334(1):269-77. doi: 10.1124/jpet.110.167379. Epub 2010 Apr 2.

18.
19.

Peripheral elevation of IGF-1 fails to alter Abeta clearance in multiple in vivo models.

Lanz TA, Salatto CT, Semproni AR, Marconi M, Brown TM, Richter KE, Schmidt K, Nelson FR, Schachter JB.

Biochem Pharmacol. 2008 Mar 1;75(5):1093-103. Epub 2007 Nov 12.

PMID:
18076866
20.

Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139.

Lanz TA, Karmilowicz MJ, Wood KM, Pozdnyakov N, Du P, Piotrowski MA, Brown TM, Nolan CE, Richter KE, Finley JE, Fei Q, Ebbinghaus CF, Chen YL, Spracklin DK, Tate B, Geoghegan KF, Lau LF, Auperin DD, Schachter JB.

J Pharmacol Exp Ther. 2006 Nov;319(2):924-33. Epub 2006 Aug 18.

22.
24.
25.
26.

H2 histaminergic control of inhibition of eating induced by intragastric NaCl in rats.

Kraly FS, Katz JB, Burchard AE, Case C, Gabriel VA, Lanz TA, Mikkelsen ME, Sokol MB.

Physiol Behav. 1998 Aug;65(1):105-13.

PMID:
9811372

Supplemental Content

Support Center